LOS ANGELES, Jan. 23 /PRNewswire-FirstCall/ -- NFL Hall of Fame wide receiver and broadcaster, Michael Irvin has joined the unparalleled list of current and former celebrities and professional athletes to have provided their names and likenesses to support the deployment of Athletes for Life's ("AFL's) network - including the revolutionary Signalife technologies - to eradicate late-stage cardiovascular disease. Mr. Irvin had an unparalleled career and was the ultimate "possession receiver" who was also a pure - undeniable -- game breaker. He is regarded as one of the most successful wide receivers in the history of professional football, winning three Super Bowls, and nicknamed the "playmaker." Irvin finished his career with 750 receptions (10th all-time) for 11,904 yards (9th all-time) and 65 touchdowns. His 47 100-yard receiving games remains the third most in NFL history, behind Hall of Famers Jerry Rice (65) and Don Maynard (50). Mr. Rice is also an Athletes for Life member for purposes of ridding society of the same fate brought about by late-stage cardiovascular disease. Lowell Harmison commented: "We cannot level the playing field for all people of all demographic groups without having legendary superstars like Mr. Irvin who see the vision like we do. Only with early intervention and effective, accurate care can the problem of cardiovascular disease be effectively dealt with. We are extremely excited that Mr. Irvin sees the vision and the importance of this project to his friends, family and those to whom he is a role model." Willie Gault, AFL's founder, stated that "it is rare to have one of my personal heroes stand alongside me to fight this disease. It is an easy equation, involving early detection and effective care. As athletes, we know that the heart must be at stress in order to accurately determine and predict its likely reaction to the challenges created throughout a patient's lifetime. I am so proud and encouraged by having my friend Michael Irvin join the overwhelming number of athletes who have simply decided that they are going to make the difference." About Signalife Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.signalife.com/. Clear Data. Trusted Results. About Athletes for Life Athletes for Life is a Non-Profit Foundation containing dozens of famous role models and athletes who are tired of having their friends die at early ages - or have invasive heart procedures - when there is no reason for our advanced society to be so backward. AFL is committed to - and does in fact - bring new technologies to healthcare, it brings life mobiles to communities so that health care comes to the masses and not visa versa, it provides foundational support for health care facilities and hospitals, and "levels the playing field" for all demographic groups of cultures through competent health care facilities and education with the role models and athletes who have made our lives unique in decades of professional sports. Caution Regarding Forward-Looking Statements Statements in this release that are not strictly historical are "forward- looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission. DATASOURCE: Signalife, Inc. CONTACT: Kevin Kading for Signalife, Inc., +1-212-918-4606 Web site: http://www.signalife.com/

Copyright